Impact of bone marrow fibrosis on outcomes of allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

• Published in: Bone marrow transplantation (Basingstoke)
• Main Authors: Zhang, Haixiao, Guo, Wenwen, Wang, Jiali, Lu, Ni, Zheng, Xinhui, Sun, Qi, Xia, Yonghui, Zhang, Rongli, Chen, Xin, Ma, Qiaoling, Yang, Donglin, Pang, Aiming, Wei, Jialin, He, Yi, Feng, Sizhou, Han, Mingzhe, Zhai, Weihua, Jiang, Erlie
• Format: Journal Article
• Language: English
• Published: England 27.08.2024
• ISSN: 1476-5365; 1476-5365
• DOI: 10.1038/s41409-024-02402-3

Bone marrow fibrosis (BMF) of unknown etiology was common in hematological malignancies, but its prognostic value for acute myeloid leukemia (AML) is unclear. We interrogated data from 532 newly diagnosed subjects with AML receiving allogeneic hematological stem cell transplantation to evaluate the prognostic impact of BMF on transplant outcomes. Using the European consensus on the grading of BMF at diagnosis, 255 (48%) subjects were BMF-0, 209 (39%), BMF-1 and 68 (13%), BMF-2-3. Subjects with BMF-2-3 had poor overall survival (P < 0.001), disease-free survival (P < 0.001) and a higher incidence of relapse (CIR, P < 0.001). Multi-variable analyses in subjects achieving pre-transplant complete remission showed BMF-2-3 was an independent risk factor for CIR (Hazard Ratio [HR] = 2.17, (95% CI, 1.11, 4,24); P = 0.02). Furthermore, BMF-2-3 group showed delayed neutrophil and platelet engraftment and delayed B cell recovery post-transplantation. These findings demonstrate the significance of BMF in transplant outcomes and attract more attention to AML with BMF.